Precision Biosciences Submitted Clinical Trial Applications To Initiate A Phase 1 Study Evaluating PBGENE-HBV, In Vivo Gene Editing Program Designed To Potentially Cure Chronic Hepatitis B Virus
Portfolio Pulse from Benzinga Newsdesk
Precision Biosciences has submitted clinical trial applications for a Phase 1 study of PBGENE-HBV, an in vivo gene editing program aimed at potentially curing chronic Hepatitis B Virus.
September 30, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Precision Biosciences has submitted applications for a Phase 1 trial of PBGENE-HBV, a gene editing program targeting chronic Hepatitis B. This marks a significant step in their biotech advancements.
The submission of clinical trial applications for PBGENE-HBV is a positive development for Precision Biosciences, indicating progress in their gene editing capabilities. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100